- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ezetimibe with Moderate-intensity Statin effective initial treatment option for patients with acute ischemic cerebrovascular disease: Study
A recent study published in the Journal of Stroke and Cerebrovascular Diseases found that a moderate-intensity statin combined with ezetimibe could be a potential therapy for high-risk stroke patients. This discovery challenges conventional wisdom regarding high-intensity statin therapy, suggesting a more effective and safer alternative.
This randomized controlled trial involved participants with acute ischemic cerebrovascular disease and compared the efficacy and safety of two lipid-lowering regimens which is moderate-intensity statin with ezetimibe against high-intensity statin alone. The results unveiled that doubling the dosage of statin drugs did not enhance the achievement rate of LDL-C target or provide additional clinical benefits, contrary to the previous assumptions. Instead, it significantly increased the risk of adverse reactions.
The patients receiving the moderate-intensity statin with ezetimibe combination showed remarkable improvements. The study revealed that this regimen not only improved the achievement rate of LDL-C but also led to a higher reduction in LDL-C levels when compared to the high-intensity statin group. The safety profiles between the two groups were comparable that indicates the moderate-intensity statin with ezetimibe could be considered as an initial treatment option for acute ischemic cerebrovascular disease patients.
This study challenges the traditional approach to lipid-lowering therapy in stroke patients. It highlights the potential benefits of a more balanced approach using moderate-intensity statin with ezetimibe by offering both efficacy and safety. This research opens new opportunities for stroke management that provides the clinicians with an alternative strategy to reduce the risk of stroke recurrence without compromising the safety of the patients.
Source:
Lv, X., Liu, X., Peng, Y., Li, W., Wang, J., Chen, X., Lei, J., Tang, C., Luo, S., Mai, W., Cai, Y., Fan, Q., Chenhao, L., & Zhang, L. (2024). Medium-intensity statin with ezetimibe versus high-intensity statin in acute ischemic cerebrovascular disease (MESIA):a randomized clinical trial. In Journal of Stroke and Cerebrovascular Diseases (p. 107647). Elsevier BV. https://doi.org/10.1016/j.jstrokecerebrovasdis.2024.107647
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751